Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Patient perceptions of clear/almost clear skin in moderate‐to‐severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey
April W. Armstrong, Suzanne Jarvis, Wolf‐­Henning Boehncke, et al.
Journal of the European Academy of Dermatology and Venereology (2018) Vol. 32, Iss. 12, pp. 2200-2207
Open Access | Times Cited: 51

Showing 1-25 of 51 citing articles:

Clinical Goals and Barriers to Effective Psoriasis Care
Bruce Strober, Joelle M. van der Walt, April W. Armstrong, et al.
Dermatology and Therapy (2018) Vol. 9, Iss. 1, pp. 5-18
Open Access | Times Cited: 84
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations
Paolo Gisondi, Mark S. Talamonti, Andrea Chiricozzi, et al.
Dermatology and Therapy (2021) Vol. 11, Iss. 1, pp. 235-252
Open Access | Times Cited: 57
Profile of dermatological consultations in Brazil (2018)
Hélio Amante Miot, Gerson Oliveira Penna, Andréa Horta Machado, et al.
Anais Brasileiros de Dermatologia (2018) Vol. 93, Iss. 6, pp. 916-928
Open Access | Times Cited: 61
Patient Perspectives on Psoriatic Disease Burden: Results from the Global Psoriasis and Beyond Survey
April W. Armstrong, Barbra Bohannan, S. Mburu, et al.
Dermatology (2023) Vol. 239, Iss. 4, pp. 621-634
Open Access | Times Cited: 20
Stigmatization in Patients With Psoriasis: A Mini Review
Hanlin Zhang, Zihan Yang, Keyun Tang, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 39
Characteristics and outcomes of patients treated with apremilast in the real world: results from the APPRECIATE study
Matthias Augustin, C. Elise Kleyn, Curdin Conrad, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 1, pp. 123-134
Open Access | Times Cited: 34
Clinical and nutritional management of very-low-calorie ketogenic diet (VLCKD) in patients with psoriasis and obesity: a practical guide for the nutritionist
Luigi Barrea, Massimiliano Caprio, Elisabetta Camajani, et al.
Critical Reviews in Food Science and Nutrition (2022) Vol. 63, Iss. 31, pp. 10775-10791
Closed Access | Times Cited: 22
Perception and determinants of stigmatization of people with psoriasis in the German population
Rachel Sommer, Janine Topp, Ulrich Mrowietz, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 34, Iss. 12, pp. 2846-2855
Open Access | Times Cited: 29
Efficacy of Therapy with the Interleukin-23 Inhibitor а Guselkumab and Quality of Life Indicators in Patients with Psoriasis
И. С. Владимирова, Л. С. Круглова
Effective Pharmacotherapy (2024) Vol. 20, Iss. 1, pp. 18-26
Open Access | Times Cited: 3
Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States
Steven R. Feldman, Stephane A. Régnier, Alexandra Chirilov, et al.
Journal of the American Academy of Dermatology (2019) Vol. 80, Iss. 6, pp. 1650-1657
Open Access | Times Cited: 27
Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study
Kristian Reich, April W. Armstrong, Peter Foley, et al.
American Journal of Clinical Dermatology (2020) Vol. 21, Iss. 6, pp. 881-890
Closed Access | Times Cited: 26
Secukinumab treatment leads to normalization of quality of life and disease symptoms in psoriasis patients with or without prior systemic psoriasis therapy: the PROSE study results
Matthias Augustin, E. Daudén, Ulrich Mrowietz, et al.
Journal of the European Academy of Dermatology and Venereology (2020) Vol. 35, Iss. 2, pp. 431-440
Open Access | Times Cited: 24
Could Targeted Pharmacotherapies Exert a “Disease Modification Effect” in Patients with Chronic Plaque Psoriasis?
Francesco Bellinato, Andrea Chiricozzi, Stefano Piaserico, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 21, pp. 12849-12849
Open Access | Times Cited: 13
Mesenchymal Stem Cells and Psoriasis: Systematic Review
Federico Diotallevi, Mariangela Di Vincenzo, Emanuela Martina, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 23, pp. 15080-15080
Open Access | Times Cited: 13
Genital Psoriasis and Associated Factors of Sexual Avoidance – A People-centered Cross-sectional Study in Germany
Maximilian Schielein, Linda Tizek, Barbara Schuster, et al.
Acta Dermato Venereologica (2020) Vol. 100, Iss. 10, pp. adv00151-adv00151
Open Access | Times Cited: 17
The impact of complete clearance and almost complete clearance of psoriasis on quality of life: a literature review
Nicole Boswell, Madison K. Cook, Esther A. Balogh, et al.
Archives of Dermatological Research (2022) Vol. 315, Iss. 4, pp. 699-706
Closed Access | Times Cited: 11
Apremilast Use in Severe Psoriasis: Real-World Data from Central and Eastern Europe
Petra Cetkovská, Iva Dediol, Marija Šola, et al.
Advances in Therapy (2023) Vol. 40, Iss. 4, pp. 1787-1802
Open Access | Times Cited: 6
The Importance of Achieving Clear or Almost Clear Skin for Patients: Results from the Nordic Countries of the Global "Clear about Psoriasis" Patient Survey
Mads Kirchheiner Rasmussen, M Enger, A Dahlborn, et al.
Acta Dermato Venereologica (2018) Vol. 99, Iss. 2, pp. 158-163
Open Access | Times Cited: 17
A real‐world, non‐interventional, prospective study of the effectiveness and safety of apremilast in bio‐naïve adults with moderate plaque psoriasis treated in the routine care in Greece – the ‘APRAISAL’ study
D. Ioannides, Nikolaos Antonakopoulos, Vasiliki Chasapi, et al.
Journal of the European Academy of Dermatology and Venereology (2022) Vol. 36, Iss. 11, pp. 2055-2063
Closed Access | Times Cited: 9
Histone deacetylase inhibitors as a potential new treatment for psoriatic disease and other inflammatory conditions
Jehan Mohammad Nazri, Κατερίνα Οικονομοπούλου, Elvin D. de Araujo, et al.
Critical Reviews in Clinical Laboratory Sciences (2023) Vol. 60, Iss. 4, pp. 300-320
Closed Access | Times Cited: 5
Cumulative life course impairment in patients with dermatological diseases, with a focus on psoriasis
Ricardo Romiti, Renata Ferreira Magalhães, Gleison Vieira Duarte
Anais Brasileiros de Dermatologia (2023) Vol. 99, Iss. 2, pp. 269-276
Open Access | Times Cited: 5
Elevating the Standard of Care for Patients with Psoriasis: ‘Calls to Action’ from Epicensus, a Multistakeholder Pan-European Initiative
Jan Kořen, Jo Lambert, Simon Francis Thomsen, et al.
Dermatology and Therapy (2022) Vol. 13, Iss. 1, pp. 245-268
Open Access | Times Cited: 8
Patient Perspectives of the Impact of Psoriatic Disease on Quality-of-Life in India: Sub-analysis from the Global Psoriasis and Beyond Survey
B. S. Chandrashekar, Chitra Nayak, Bikash Ranjan Kar, et al.
Indian Dermatology Online Journal (2024) Vol. 15, Iss. 2, pp. 233-241
Open Access | Times Cited: 1
Patient Perspectives on the Prevalence and Burden of Intertriginous Psoriasis: Results from a National Survey of Adults with Psoriasis in the United States
Teri M. Greiling, Melodie Young, Melissa Seal, et al.
Dermatology and Therapy (2024) Vol. 14, Iss. 7, pp. 1839-1847
Open Access | Times Cited: 1
ANALYSIS OF THE OPINIONS OF WOMEN AND MEN OF DIFFERENT AGES ABOUT PSORIASIS
Natalia Jażdżewska, Halina Tkaczenko, Natalia Kurhaluk
Biota Human Technology (2024), Iss. 1, pp. 143-175
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top